A Multicenter, Open-label, Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Patients with Severe Eosinophilic Asthma on High-Dose Inhaled Corticosteroid plus Long-acting ß2 Ag

    Project: Other project

    Project Details

    StatusFinished
    Effective start/end date10/19/18 → 10/18/20

    Funding

    • AstraZeneca LP: $6,311.54